Feb 01, 2014

AYX1 Article Published in PAIN Journal

“Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury”

SAN FRANCISCO, CALIF., February 1, 2014 – Adynxx’s lead product candidate, AYX1, was featured in the February issue of PAIN, the Journal of the International Association for the Study of Pain.  The article, titled “Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury,” describes the pre-clinical pharmacology of AYX1.

Authors included Adynxx founder and Chief Scientific Officer Julien Mamet, Adynxx Chief Medical Officer Don Manning, Adynxx Vice President, Regulatory Affairs and Product Development Scott Harris; Adynxx Scientific Advisory Board members Tony Yaksh, William Schmidt, and David Yeomans; and Michael Klukinov, Shelle A. Malkmus, Samantha Williams, Bradley K. Taylor, Renee R. Donahue, Frank Porreca, Jennifer Y. Xie, Janice Oyarzo, Timothy J. Brennan, and Alberto Subieta.

The abstract of the article is available at PAIN Journal Online.

About Adynxx

Adynxx, located in San Francisco, California, is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

Adynxx’s lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery. Adynxx has completed Phase 1 and Phase 2 clinicals trial of AYX1.